[{"arm_notes": "", "treatment_id": null, "treatment_name": "TODO Treatment - DrugsControl group: Patients with severe Covid-19 who receive intratracheal normal saline.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "TODO Treatment - DrugsIntervention group: Patients with severe COVID-19 under mechanical ventilation who receive intratracheal epinephrine. At the beginning of enrollment of patients in this group, for each patient in this group, 3 ml of adrenaline one in 1000 (manufactured by Iran Hormone Pharmaceutical Company) plus 2 ml of normal saline 0.9% (manufactured by Shahid Ghazi Pharmaceutical Company) is prescribed in a nebulized form. And the consequences mentioned in the presented plan are measured in the relevant schedule.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 470, "treatment_name": "Epinephrine", "treatment_type": "Cardiovascular agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]